Press Releases

Investors & Media

 
Press Releases
  Date Title and Summary View
Dec 20, 2016
WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Michael Davidson, M.D., as chief medical officer effective December 19, 2016.  His respons...
Dec 5, 2016
Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA trials with MIN-101 and MIN-117 WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biop...
Nov 10, 2016
WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2016 London Healthcare Conference on November 17, 2016 at 12:40 p.m. ...
Nov 3, 2016
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the third quarter ended September 30, 2016. "Recent high...
Oct 27, 2016
Management to host conference call WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third...
Oct 26, 2016
Oct 13, 2016
WALTHAM, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the acceptance of four abstracts for presentation at the 55th Annual Meeting of the American College of Neu...
Sep 26, 2016
Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central n...
Sep 2, 2016
WALTHAM, Mass., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the 23rd Annual NewsMakers in the Biotech Industry conference in New Yo...
Aug 4, 2016
Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major depressive disorder WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) --  Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical com...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase